Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (401-410 of 676) with videos related to

Pageof 68
Sort By:
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemiaFrancis J Giles, Jorge E Cortes, Deborah A Thomas, et al.
Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.
Cancer Treatment Reviews|March 11, 2017
Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasisR Costa, N Gill, A W Rademaker, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell linesHatice Duzkale, Iman Jilani, Nada Orsolic, et al.
Breast (Edinburgh, Scotland)|June 16, 2017
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclibR Costa, R B Costa, Sarah M Talamantes, et al.
Expert Review of Hematology|November 25, 2010
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd studyFrancis J Giles, Gianantonio Rosti, Photis Beris, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of CancerAmy Walz, Andrey Ugolkov, Sunandana Chandra, et al.
Cancer|December 24, 1997
Comparison of Technetium-99m sestamibi and indium-111 octreotide imaging in a patient with Ewing's sarcoma before and after stem cell transplantationF J Giles, A D Waxman, K N Nguyen, et al.
Pageof 68

Showing results (401-410 of 676) with videos related to

Sort By:
Pageof 68
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemiaFrancis J Giles, Jorge E Cortes, Deborah A Thomas, et al.
Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.
Cancer Treatment Reviews|March 11, 2017
Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasisR Costa, N Gill, A W Rademaker, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell linesHatice Duzkale, Iman Jilani, Nada Orsolic, et al.
Breast (Edinburgh, Scotland)|June 16, 2017
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclibR Costa, R B Costa, Sarah M Talamantes, et al.
Expert Review of Hematology|November 25, 2010
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd studyFrancis J Giles, Gianantonio Rosti, Photis Beris, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of CancerAmy Walz, Andrey Ugolkov, Sunandana Chandra, et al.
Cancer|December 24, 1997
Comparison of Technetium-99m sestamibi and indium-111 octreotide imaging in a patient with Ewing's sarcoma before and after stem cell transplantationF J Giles, A D Waxman, K N Nguyen, et al.
Pageof 68